Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with ...

Immunotherapy plus chemotherapy versus chemotherapy alone in metastatic non–small-cell lung cancer: A systematic review with meta-analysis.. JCO 37 , e20700-e20700 (2019). DOI: ...

It's entitled "Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with a ...

Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis of randomized controlled trials. Isadora Mamede ...

In the MMR-proficient cohort, median PFS reached 11.1 months with the addition of pembrolizumab versus 8.5 months with chemotherapy alone (HR 0.60, 95% CI 0.46-0.78, P<0.0001).

Yet immunotherapy has faced some prominent setbacks. In August a clinical trial of the Bristol-Myers Squibb drug Opdivo, or nivolumab, for a group of patients with newly diagnosed lung cancer ...

Combining immunotherapy with chemotherapy may improve survival in extensive-stage small cell lung cancer without increasing treatment-related toxicity. The study showed a median overall survival ...

The combination of durvalumab with chemotherapy, versus chemotherapy alone, in conjunction with in-depth genomic characterization of biospecimens from patients with mesothelioma, is being further ...

SAN ANTONIO — An immunotherapy-chemotherapy combination conferred benefit for certain patients with high-risk breast cancer, ... (10.2% vs. 8.1%), denoting less residual cancer burden.

Tecentriq plus chemotherapy reduced recurrence or death risk by 50% in stage III colorectal cancer with deficient mismatch repair. The combination therapy achieved a 3-year disease-free survival rate ...

Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year.

Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer Study finds patients with advanced non-small cell lung cancer and STK11 and/or KEAP1 mutations had ...